New insights into the structure and function of the pseudokinase domain in JAK2

Biochemical Society Transactions

Volumn 41, Issue 4, 2013, Pages 1002-1007

  Silvennoinen, Olli ^a,b   Ungureanu, Daniela ^a   Niranjan, Yashavanthi ^a   Hammaren, Henrik ^a   Bandaranayake, Rajintha ^c   Hubbard, Stevan R ^c  

^a TAMPERE UNIVERSITY OF TECHNOLOGY   (Finland)

^b TAMPERE UNIVERSITY HOSPITAL   (Finland)

^c NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Cytokine; Janus kinase (JAK); Pseudokinase; Signalling; Structure

Indexed keywords

ADENOSINE TRIPHOSPHATE MAGNESIUM; JANUS KINASE 2; PROTEIN KINASE; PSEUDOKINASE; UNCLASSIFIED DRUG;

ALPHA HELIX; AMINO TERMINAL SEQUENCE; ARTICLE; CATALYSIS; CONFORMATIONAL TRANSITION; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME PHOSPHORYLATION; ENZYME STABILITY; ENZYME STRUCTURE; HUMAN; MYELOPROLIFERATIVE NEOPLASM; NONHUMAN; POLYCYTHEMIA VERA; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN PROTEIN INTERACTION; REGULATORY MECHANISM; SEQUENCE HOMOLOGY; SIGNAL TRANSDUCTION; STRUCTURE ANALYSIS; WILD TYPE;

HUMANS; JANUS KINASE 2; MODELS, MOLECULAR; MUTATION; PHOSPHORYLATION; POLYCYTHEMIA VERA; PROTEIN CONFORMATION; PROTEIN KINASES; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 84880530413     PISSN: 03005127     EISSN: 14708752     Source Type: Journal    
DOI: 10.1042/BST20130005     Document Type: Article

References (37)

1. Ihle, J.N., Witthuhn, B.A., Quelle, F.W., Yamamoto, K. and Silvennoinen, O. (1995) Signaling through the hematopoietic cytokine receptors. Annu. Rev. Immunol. 13, 369-398
2. Imada, K. and Leonard, W.J. (2000) The Jak-STAT pathway. Mol. Immunol. 37, 1-11
3. Silvennoinen, O., Witthuhn, B.A., Quelle, F.W., Cleveland, J.L., Yi, T. and Ihle, J.N. (1993) Structure of the murine Jak2 protein-tyrosine kinase and its role in interleukin 3 signal transduction. Proc. Natl. Acad. Sci. U.S.A. 90, 8429-8433
4. Zhou, Y.J., Chen, M., Cusack, N.A., Kimmel, L.H., Magnuson, K.S., Boyd, J.G., Lin, W., Roberts, J.L., Lengi, A., Buckley, R.H. et al. (2001) Unexpected effects of FERM domain mutations on catalytic activity of Jak3: structural implication for Janus kinases. Mol. Cell 8, 959-969
5. Haan, S., Margue, C., Engrand, A., Rolvering, C., Schmitz-Van de Leur, H., Heinrich, P.C., Behrmann, I. and Haan, C. (2008) Dual role of the Jak1 FERM and kinase domains in cytokine receptor binding and in stimulation-dependent Jak activation. J. Immunol. 180, 998-1007
6. Kile, B.T., Nicola, N.A. and Alexander, W.S. (2001) Negative regulators of cytokine signaling. Int. J. Hematol. 73, 292-298
7. Feener, E.P., Rosario, F., Dunn, S.L., Stancheva, Z. and Myers, Jr, M.G. (2004) Tyrosine phosphorylation of Jak2 in the JH2 domain inhibits cytokine signaling. Mol. Cell. Biol. 24, 4968-4978
8. Ishida-Takahashi, R., Rosario, F., Gong, Y., Kopp, K., Stancheva, Z., Chen, X., Feener, E.P. and Myers, Jr, M.G. (2006) Phosphorylation of Jak2 on Ser523 inhibits Jak2-dependent leptin receptor signaling. Mol. Cell. Biol. 26, 4063-4073
9. Robertson, S.A., Koleva, R.I., Argetsinger, L.S., Carter-Su, C., Marto, J.A., Feener, E.P. and Myers, Jr, M.G. (2009) Regulation of Jak2 function by phosphorylation of Tyr317 and Tyr637 during cytokine signaling. Mol. Cell. Biol. 29, 3367-3378
10. Saharinen, P. and Silvennoinen, O. (2002) The pseudokinase domain is required for suppression of basal activity of Jak2 and Jak3 tyrosine kinases and for cytokine-inducible activation of signal transduction. J. Biol. Chem. 277, 47954-47963
11. Matsuda, T., Feng, J., Witthuhn, B.A., Sekine, Y. and Ihle, J.N. (2004) Determination of the transphosphorylation sites of Jak2 kinase. Biochem. Biophys. Res. Commun. 325, 586-594
12. Neubauer, H., Cumano, A., Muller, M., Wu, H., Huffstadt, U. and Pfeffer, K. (1998) Jak2 deficiency defines an essential developmental checkpoint in definitive hematopoiesis. Cell 93, 397-409
13. Argetsinger, L.S., Kouadio, J.L., Steen, H., Stensballe, A., Jensen, O.N. and Carter-Su, C. (2004) Autophosphorylation of JAK2 on tyrosines 221 and 570 regulates its activity. Mol. Cell. Biol. 24, 4955-4967
14. Argetsinger, L.S., Stuckey, J.A., Robertson, S.A., Koleva, R.I., Cline, J.M., Marto, J.A., Myers, Jr, M.G. and Carter-Su, C. (2010) Tyrosines 868, 966, and 972 in the kinase domain of JAK2 are autophosphorylated and required for maximal JAK2 kinase activity. Mol. Endocrinol. 24, 1062-1076
15. Mazurkiewicz-Munoz, A.M., Argetsinger, L.S., Kouadio, J.L., Stensballe, A., Jensen, O.N., Cline, J.M. and Carter-Su, C. (2006) Phosphorylation of JAK2 at serine 523: a negative regulator of JAK2 that is stimulated by growth hormone and epidermal growth factor. Mol. Cell. Biol. 26, 4052-4062
16. Funakoshi-Tago, M., Pelletier, S., Matsuda, T., Parganas, E. and Ihle, J.N. (2006) Receptor specific downregulation of cytokine signaling by autophosphorylation in the FERM domain of Jak2. EMBO J. 25, 4763-4772
17. Kurzer, J.H., Argetsinger, L.S., Zhou, Y.J., Kouadio, J.L., O'Shea, J.J. and Carter-Su, C. (2004) Tyrosine 813 is a site of JAK2 autophosphorylation critical for activation of JAK2 by SH2-Bβ. Mol. Cell. Biol. 24, 4557-4570
18. Karaghiosoff, M., Neubauer, H., Lassnig, C., Kovarik, P., Schindler, H., Pircher, H., McCoy, B., Bogdan, C., Decker, T., Brem, G. et al. (2000) Partial impairment of cytokine responses in Tyk2-deficient mice. Immunity 13, 549-560
19. Shimoda, K., Kato, K., Aoki, K., Matsuda, T., Miyamoto, A., Shibamori, M., Yamashita, M., Numata, A., Takase, K., Kobayashi, S. et al. (2000) Tyk2 plays a restricted role in IFNα signaling, although it is required for IL-12-mediated T cell function. Immunity 13, 561-571
20. Saharinen, P., Takaluoma, K. and Silvennoinen, O. (2000) Regulation of the Jak2 tyrosine kinase by its pseudokinase domain. Mol. Cell. Biol. 20, 3387-3395
21. Hanratty, W.P. and Dearolf, C.R. (1993) The Drosophila tumorous-lethal hematopoietic oncogene is a dominant mutation in the hopscotch locus. Mol. Gen. Genet. 238, 33-37
22. Russell, S.M., Tayebi, N., Nakajima, H., Riedy, M.C., Roberts, J.L., Aman, M.J., Migone, T.S., Noguchi, M., Markert, M.L., Buckley, R.H. et al. (1995) Mutation of Jak3 in a patient with SCID: essential role of Jak3 in lymphoid development. Science 270, 797-800
23. Baxter, E.J., Scott, L.M., Campbell, P.J., East, C., Fourouclas, N., Swanton, S., Vassiliou, G.S., Bench, A.J., Boyd, E.M., Curtin, N. et al. (2005) Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet 365, 1054-1061
24. James, C., Ugo, V., Casadevall, N., Constantinescu, S.N. and Vainchenker, W. (2005) A JAK2 mutation in myeloproliferative disorders: pathogenesis and therapeutic and scientific prospects. Trends Mol. Med. 11, 546-554
25. Kralovics, R., Passamonti, F., Buser, A.S., Teo, S.S., Tiedt, R., Passweg, J.R., Tichelli, A., Cazzola, M. and Skoda, R.C. (2005) A gain-of-function mutation of JAK2 in myeloproliferative disorders. N. Engl. J. Med. 352, 1779-1790
26. Levine, R.L., Wadleigh, M., Cools, J., Ebert, B.L., Wernig, G., Huntly, B.J., Boggon, T.J., Wlodarska, I., Clark, J.J., Moore, S. et al. (2005) Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell 7, 387-397
27. Ungureanu, D., Wu, J., Pekkala, T., Niranjan, Y., Young, C., Jensen, O.N., Xu, C.F., Neubert, T.A., Skoda, R.C., Hubbard, S.R. and Silvennoinen, O. (2011) The pseudokinase domain of JAK2 is a dual-specificity protein kinase that negatively regulates cytokine signaling. Nat. Struct. Mol. Biol. 18, 971-976
28. Hall, T., Emmons, T.L., Chrencik, J.E., Gormley, J.A., Weinberg, R.A., Leone, J.W., Hirsch, J.L., Saabye, M.J., Schindler, J.F., Day, J.E. et al. (2010) Expression, purification, characterization and crystallization of non-and phosphorylated states of JAK2 and JAK3 kinase domain. Protein Expression Purif. 69, 54-63
29. Scott, L.M., Beer, P.A., Bench, A.J., Erber, W.N. and Green, A.R. (2007) Prevalance of JAK2 V617F and exon 12 mutations in polycythaemia vera. Br. J. Haematol. 139, 511-512
30. Bercovich, D., Ganmore, I., Scott, L.M., Wainreb, G., Birger, Y., Elimelech, A., Shochat, C., Cazzaniga, G., Biondi, A., Basso, G. et al. (2008) Mutations of JAK2 in acute lymphoblastic leukaemias associated with Down's syndrome. Lancet 372, 1484-1492
31. Bandaranayake, R.M., Ungureanu, D., Shan, Y., Shaw, D.E., Silvennoinen, O. and Hubbard, S.R. (2012) Crystal structures of the JAK2 pseudokinase domain and the pathogenic mutant V617F. Nat. Struct. Mol. Biol. 19, 754-759
32. Boggon, T.J., Li, Y., Manley, P.W. and Eck, M.J. (2005) Crystal structure of the Jak3 kinase domain in complex with a staurosporine analogue. Blood 106, 996-1002
33. Thoma, G., Nuninger, F., Falchetto, R., Hermes, E., Tavares, G.A., Vangrevelinghe, E. and Zerwes, H.G. (2011) Identification of a potent Janus kinase 3 inhibitor with high selectivity within the Janus kinase family. J. Med. Chem. 54, 284-288
34. Williams, N.K., Bamert, R.S., Patel, O., Wang, C., Walden, P.M., Wilks, A.F., Fantino, E., Rossjohn, J. and Lucet, I.S. (2009) Dissecting specificity in the Janus kinases: the structures of JAK-specific inhibitors complexed to the JAK1 and JAK2 protein tyrosine kinase domains. J. Mol. Biol. 387, 219-232
35. Lucet, I.S., Fantino, E., Styles, M., Bamert, R., Patel, O., Broughton, S.E., Walter, M., Burns, C.J., Treutlein, H., Wilks, A.F. and Rossjohn, J. (2006) The structural basis of Janus kinase 2 inhibition by a potent and specific pan-Janus kinase inhibitor. Blood 107, 176-183
36. Jura, N., Shan, Y., Cao, X., Shaw, D.E. and Kuriyan, J. (2009) Structural analysis of the catalytically inactive kinase domain of the human EGF receptor 3. Proc. Natl. Acad. Sci. U.S.A. 106, 21608-21613
37. Shi, F., Telesco, S.E., Liu, Y., Radhakrishnan, R. and Lemmon, M.A. (2010) ErbB3/HER3 intracellular domain is competent to bind ATP and catalyze autophosphorylation. Proc. Natl. Acad. Sci. U.S.A. 107, 7692-7697